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Purpose or Objective: With its high sensitivity and specificity 
compared to MRI, amino-acid PET is increasingly used for 
diagnosis and radiotherapy treatment planning in recurrent 
glioblastoma. Defining the exact tumor extent is exceedingly 
crucial for planning of high-precision reirradiation (SFRT, 
IGRT). Up to date, no standard for a visual or (semi-
)automatic method for GTV delineation in amino-acid PET 
exists. In the present study, we investigated whether pre-
defined PET windows would lead to a more consistent 
contouring of the tumor and – as a model with MRI-defined 
ground truth – normal tissues among observers. 
 
Material and Methods: Pre-reirradiation imaging data (MRI 
and FET-PET) of 17 patients with recurrent glioblastoma were 
retrospectively evaluated. Two different pre-set window 
levels were created for FET-PET data, either normalized to 
SUVmax or normalized to the SUVmean of the contralateral 
non-tumor bearing hemisphere (SUVmean contra). The GTV 
was delineated in both data sets by 5 observers (radiation 
oncology and nuclear medicine specialists). Additionally, 
normal tissue with (superior sagittal sinus or lacrimal gland) 
and without physiological FET uptake (eye and lateral 
ventricle) were contoured. A reference contour for normal 
tissues was delineated in contrast-enhanced T1 MRI, and 
overlap volume (OV) and Kappa index (KI) were calculated for 
each structure. 
 
Results: GTV volumes were larger by trend when normalized 
to SUVmean contra, but not significantly different between 
the two PET image normalization methods (18,72 ± 17,44 ml 
for SUVmean contra vs. 14,68 ± 12,34 ml for SUVmax, 
p=0,41). Linear regression of inter-observer variability 
showed a significantly better agreement of the GTV contours 
when PET images were normalized to SUVmean contra 
(t=3,5). The intra-method comparison of PET data normalized 
to SUVmax or SUVmean contra showed the highest consensus 
for GTV (OVmean=0,5 and 0,52 and KI=0,64 and 0,66, 
respectively), whereas the lacrimal gland was the structure 
with the least congruency (OVmean=0,37 and 0,42 and 
KI=0,46 and 0,52, respectively). There was no overall 
significant difference between both PET windows (OVmean 
p=0,83;KI p=0,87). Correlation of normal tissue contours with 
MRI reference was poor (SUVmax vs. MRI: OVmean 0,11-0,37, 
KI 0,19-0,53; SUVmean contra vs. MRI: OVmean 0,13-0,36, KI 
0,22-0,52) and not significantly different between the two 
normalization methods (p=0,7 and 0,89 for OVmean and KI, 
respectively). 
 
Conclusion: Normalization on the SUVmean of the 
contralateral hemisphere in FET-PET images helps to reduce 
inter-observer variability in the visual delineation of the GTV 
in patients with recurrent glioblastoma. However, neither 
improvement nor difference in the consistency of normal 
tissue delineation, as a model with MRI-defined ground truth, 
between the different windows was seen. 
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Purpose or Objective: Repetitive functional imaging during 
the course of irradiation is a promising method to identify 
non-small cell lung cancer (NSCLC) patients that have poor or 
favourable response to radiotherapy [1]. In locally advanced 
lung cancer patient, the primary tumour (PT) and involved 
lymph nodes (LN) are delineated and irradiated. It is 
currently, however, unknown if all intrathoracic lesions 
within the same patient demonstrate the same metabolic 
response. The purpose of this study was therefore to 
investigate the correspondence in response rate of the PT 
and involved LNs. 
 
Material and Methods: Eight locally advanced NSCLC patients 
included in an ongoing prospective clinical trial 
(NCT02315053) for repeat quantitative evaluation of tumour 
metabolism (using FDG-PET) weekly during treatment were 
analysed. Patients were treated with concurrent 
chemoradiation (CCRT) with curative intent, in 24 fractions 
of 2.75 Gy combined with daily cisplatin 6 mg/m2 with an 
overall treatment time of 32 days. All patients underwent a 
PET/CT for treatment planning and weekly low dose FDG 
PET/CT scans of the thorax in treatment position prior to the 
daily chemotherapy and radiotherapy administration. For the 
PT and each treated LN with a baseline SUVmax≥3 (median 3 
LNs per patient; range 2-4), the SUVmax was normalized 
separately to the baseline value at the start of treatment. 
Consistency in the response between PT and LNs was 
evaluated by Bland-Altman analysis over the cohort 
(corrected for the number of lymph nodes per patients and 
excluding the baseline used for normalization) as well as 
total least squares linear regression with the PT for each LN 
separately. 
 
Results: Considerable variability in metabolic response for 
individual time points was observed in the pooled analysis of 
all patients (Fig 1a) with Bland-Altman limits of agreement 
(LA) of 46% and a bias of 10%. Despite these LA, the 
correlation in the response between PT and LN was 
reasonably high with a median value of 0.86 with an 
interquartile range of 0.21. The median slope of the 
regression analysis was of 1.1 with an interquartile range of 
0.7, indicating that the LNs typically respond a little faster 
than the PT. However, within a patient, several involved 
lymph node stations exhibited a considerably different 
response as illustrated in Fig1b.  
 
